Clinical Report: Mitigating Surgical Site Infections Caused by Cutibacterium acnes
Overview
This randomized clinical trial evaluates the effectiveness of targeted intraoperative hygiene measures to reduce surgical site contamination with Cutibacterium acnes in male patients undergoing cardiac surgery.
Background
Cutibacterium acnes has transitioned from being considered a contaminant to a recognized pathogen in prosthetic valve endocarditis (PVE). Its prevalence in PVE cases is estimated between 3.8% and 8.0%, but may be underestimated due to its slow growth and nonspecific symptoms.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
Cutibacterium acnes is now included in the 2023 Duke–ISCVID criteria as a relevant pathogen for PVE.
The trial was conducted exclusively with male patients due to a higher incidence of C acnes infective endocarditis in this population.
Standard disinfection protocols may not fully eliminate C acnes residing in hair follicles.
Intraoperative strategies for C acnes management in cardiac surgery have not been previously established.
Patients received standard perioperative antibiotic prophylaxis with 1.5 g intravenous cefuroxime.
Clinical Implications
The findings from this trial may inform future protocols for intraoperative hygiene in cardiac surgery, particularly in male patients. Addressing C acnes as a potential pathogen could enhance surgical outcomes and reduce the incidence of postoperative infections.
Conclusion
This study underscores the need for targeted interventions to mitigate the risk of C acnes infections in cardiac surgery. Further research is warranted to establish effective intraoperative strategies.
by Isabell Moter, Sören Schubert, Ana Goncalves, Shekhar Saha, Kurosh Sarbandi, Judith Kikhney, Annette Moter, Edgar Eszlari, Christian Hagl, Walter Eichinger
The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.
